Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2014

Open Access 01-12-2014 | Research

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment

Authors: Maria Lehmann, Michèle J Hoffmann, Annemarie Koch, Scott M Ulrich, Wolfgang A Schulz, Günter Niegisch

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Login to get access

Abstract

Background

Previous studies have shown that class-I histone deacetylase (HDAC) 8 mRNA is upregulated in urothelial cancer tissues and urothelial cancer cell lines compared to benign controls. Using urothelial cancer cell lines we evaluated whether specific targeting of HDAC8 might be a therapeutic option in bladder cancer treatment.

Methods

We conducted siRNA-mediated knockdown and specific pharmacological inhibition of HDAC8 with the three different inhibitors compound 2, compound 5, and compound 6 in several urothelial carcinoma cell lines with distinct HDAC8 expression profiles. Levels of HDAC and marker proteins were determined by western blot analysis and mRNA levels were measured by quantitative real-time PCR. Cellular effects of HDAC8 suppression were analyzed by ATP assay, flow cytometry, colony forming assay and migration assay.

Results

Efficient siRNA-mediated knockdown of HDAC8 reduced proliferation up to 45%. The HDAC8 specific inhibitors compound 5 and compound 6 significantly reduced viability of all urothelial cancer cell lines (IC50 9 – 21 μM). Flow cytometry revealed only a slight increase in the sub-G1 fraction indicating a limited induction of apoptosis. Expression of thymidylate synthase was partly reduced; PARP-cleavage was not detected. The influence of the pharmacological inhibition on clonogenic growth and migration show a cell line- and inhibitor-dependent reduction with the strongest effects after treatment with compound 5 and compound 6.

Conclusions

Deregulation of HDAC8 is frequent in urothelial cancer, but neither specific pharmacological inhibition nor siRNA-mediated knockdown of HDAC8 impaired viability of urothelial cancer cell lines in a therapeutic useful manner. Accordingly, HDAC8 on its own is not a promising drug target in bladder cancer.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917. 10.1002/ijc.25516.CrossRefPubMed
2.
Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A: EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines. Eur Urol. 2014, 65 (4): 778-92. 10.1016/j.eururo.2013.11.046.CrossRefPubMed
3.
Goebell PJ, Vom Dorp F, Rodel C, Frohneberg D, Thuroff JW, Jocham D, Stief C, Roth S, Knuchel R, Schmidt KW, Kausch I, Zaak D, Wiesner C, Miller K, Sauer R, Rübben H: Noninvasive and invasive bladder cancer: diagnostics and treatment. Der Urologe Ausg A. 2006, 45: 873-884. 10.1007/s00120-006-1065-z.CrossRefPubMed
4.
Roberts JT, von der Maase H, Sengelov L, Conte PF, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M: Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol. 2006, 17 (Suppl 5): v118-122. 10.1093/annonc/mdj965.CrossRefPubMed
5.
Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI: ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013, 63: 58-66. 10.1016/j.eururo.2012.08.010.CrossRefPubMed
6.
Butler JS, Koutelou E, Schibler AC, Dent SY: Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease. Epigenomics. 2012, 4: 163-177. 10.2217/epi.12.3.PubMedCentralCrossRefPubMed
7.
Dawson MA, Kouzarides T: Cancer epigenetics: from mechanism to therapy. Cell. 2012, 150: 12-27. 10.1016/j.cell.2012.06.013.CrossRefPubMed
8.
Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, Jia W, Chen J, Yang S, Zhou F, Zhao X, Wan S, Ye R, Liang C, Liu Z, Huang P, Liu C, Jiang H, Wang Y, Zheng H, Sun L, Liu X, Jiang Z, et al: Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011, 43: 875-878. 10.1038/ng.907.CrossRefPubMed
9.
Ahmad M, Hamid A, Hussain A, Majeed R, Qurishi Y, Bhat JA, Najar RA, Qazi AK, Zargar MA, Singh SK, Saxena AK: Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy. DNA Cell Biol. 2012, 31 (Suppl 1): S62-71.PubMed
10.
Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Canc. 2001, 1: 194-202. 10.1038/35106079.CrossRef
11.
de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003, 370: 737-749. 10.1042/BJ20021321.PubMedCentralCrossRefPubMed
12.
Gregoretti IV, Lee YM, Goodson HV: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004, 338: 17-31. 10.1016/j.jmb.2004.02.006.CrossRefPubMed
13.
Witt O, Deubzer HE, Milde T, Oehme I: HDAC family: What are the cancer relevant targets?. Cancer Lett. 2009, 277: 8-21. 10.1016/j.canlet.2008.08.016.CrossRefPubMed
14.
Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Rocken C: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008, 9: 139-148. 10.1016/S1470-2045(08)70004-4.CrossRefPubMed
15.
Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G: Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008, 98: 604-610. 10.1038/sj.bjc.6604199.PubMedCentralCrossRefPubMed
16.
Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, Kobel M: Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 2008, 10: 1021-1027.PubMedCentralCrossRefPubMed
17.
Yang XJ, Seto E: The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008, 9: 206-218. 10.1038/nrm2346.PubMedCentralCrossRefPubMed
18.
Grunstein M: Histone acetylation in chromatin structure and transcription. Nature. 1997, 389: 349-352. 10.1038/38664.CrossRefPubMed
19.
Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009, 325: 834-840. 10.1126/science.1175371.CrossRefPubMed
20.
Patel J, Pathak RR, Mujtaba S: The biology of lysine acetylation integrates transcriptional programming and metabolism. Nutr Metabol. 2011, 8: 12-10.1186/1743-7075-8-12.CrossRef
21.
Gu W, Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997, 90: 595-606. 10.1016/S0092-8674(00)80521-8.CrossRefPubMed
22.
Rolef Ben-Shahar T, Heeger S, Lehane C, East P, Flynn H, Skehel M, Uhlmann F: Eco1-dependent cohesin acetylation during establishment of sister chromatid cohesion. Science. 2008, 321: 563-566. 10.1126/science.1157774.CrossRefPubMed
23.
Li Y, Shin D, Kwon SH: Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 2013, 280: 775-793.PubMed
24.
Valente S, Mai A: Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013). Expert Opin Ther Pat. 2014, 24 (4): 401-15. 10.1517/13543776.2014.877446.CrossRefPubMed
25.
Ververis K, Hiong A, Karagiannis TC, Licciardi PV: Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics. 2013, 7: 47-60.PubMedCentralPubMed
26.
Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, Tsuneyoshi M: Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep. 2007, 18: 769-774.PubMed
27.
Hu E, Chen Z, Fredrickson T, Zhu Y, Kirkpatrick R, Zhang GF, Johanson K, Sung CM, Liu R, Winkler J: Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem. 2000, 275: 15254-15264. 10.1074/jbc.M908988199.CrossRefPubMed
28.
Van den Wyngaert I, de Vries W, Kremer A, Neefs J, Verhasselt P, Luyten WH, Kass SU: Cloning and characterization of human histone deacetylase 8. FEBS Lett. 2000, 478: 77-83. 10.1016/S0014-5793(00)01813-5.CrossRefPubMed
29.
Buggy JJ, Sideris ML, Mak P, Lorimer DD, McIntosh B, Clark JM: Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem J. 2000, 350 (Pt 1): 199-205. 10.1042/0264-6021:3500199.PubMedCentralCrossRefPubMed
30.
Lee H, Rezai-Zadeh N, Seto E: Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol. 2004, 24: 765-773. 10.1128/MCB.24.2.765-773.2004.PubMedCentralCrossRefPubMed
31.
Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkühler C, Di Marco S: Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci U S A. 2004, 101: 15064-15069. 10.1073/pnas.0404603101.PubMedCentralCrossRefPubMed
32.
Waltregny D, North B, Van Mellaert F, de Leval J, Verdin E, Castronovo V: Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur J Histochem. 2004, 48: 273-290.PubMed
33.
Waltregny D, De Leval L, Glenisson W, Ly Tran S, North BJ, Bellahcene A, Weidle U, Verdin E, Castronovo V: Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol. 2004, 165: 553-564. 10.1016/S0002-9440(10)63320-2.PubMedCentralCrossRefPubMed
34.
Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O: Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009, 15: 91-99. 10.1158/1078-0432.CCR-08-0684.CrossRefPubMed
35.
Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ: A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008, 22: 1026-1034. 10.1038/leu.2008.9.CrossRefPubMed
36.
Wu J, Du C, Lv Z, Ding C, Cheng J, Xie H, Zhou L, Zheng S: The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma. Dig Dis Sci. 2013, 58: 3545-3553. 10.1007/s10620-013-2867-7.CrossRefPubMed
37.
Park SY, Jun JA, Jeong KJ, Heo HJ, Sohn JS, Lee HY, Park CG, Kang J: Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep. 2011, 25: 1677-1681.PubMed
38.
Lee H, Sengupta N, Villagra A, Rezai-Zadeh N, Seto E: Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation. Mol Cell Biol. 2006, 26: 5259-5269. 10.1128/MCB.01971-05.PubMedCentralCrossRefPubMed
39.
Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA: Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Urol Oncol. 2013, 31: 1770-1779. 10.1016/j.urolonc.2012.06.015.CrossRefPubMed
40.
Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F, Schulz WA: Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res. 2003, 282: 48-57. 10.1006/excr.2002.5647.CrossRefPubMed
41.
Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM: Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007, 17: 2874-2878. 10.1016/j.bmcl.2007.02.064.CrossRefPubMed
42.
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth. 1991, 139: 271-279. 10.1016/0022-1759(91)90198-O.CrossRef
43.
Shechter D, Dormann HL, Allis CD, Hake SB: Extraction, purification and analysis of histones. Nat Protocol. 2007, 2: 1445-1457. 10.1038/nprot.2007.202.CrossRef
44.
Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS: Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 2010, 28: 2660-2667. 10.1200/JCO.2009.25.0977.CrossRefPubMed
45.
Quan P, Moinfar F, Kufferath I, Absenger M, Kueznik T, Denk H, Zatloukal K, Haybaeck J: Effects of Targeting Endometrial Stromal Sarcoma Cells via Histone Deacetylase and PI3K/AKT/mTOR Signaling. Anticancer Res. 2014, 34: 2883-2897.PubMed
46.
Boyault C, Sadoul K, Pabion M, Khochbin S: HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene. 2007, 26: 5468-5476. 10.1038/sj.onc.1210614.CrossRefPubMed
47.
Yagi Y, Fushida S, Harada S, Kinoshita J, Makino I, Oyama K, Tajima H, Fujita H, Takamura H, Ninomiya I, Fujimura T, Ohta T, Yashiro M, Hirakawa K: Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res. 2010, 29: 149-10.1186/1756-9966-29-149.PubMedCentralCrossRefPubMed
48.
Rosik L, Niegisch G, Fischer U, Jung M, Schulz WA, Hoffmann MJ: Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Canc Biol Ther. 2014, 15: 742-57. 10.4161/cbt.28469.CrossRef
Metadata
Title
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
Authors
Maria Lehmann
Michèle J Hoffmann
Annemarie Koch
Scott M Ulrich
Wolfgang A Schulz
Günter Niegisch
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-014-0059-8

Other articles of this Issue 1/2014

Journal of Experimental & Clinical Cancer Research 1/2014 Go to the issue

Research

Expression of heparanase in soft tissue sarcomas of adults

Research

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity

Research

Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells

Research

The activation of c-Jun NH2-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells

Review

Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm

Research

In silico and Ex vivo approaches identify a role for toll-like receptor 4 in colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits